Tra­vere inks bile acid di­vesti­ture; Madri­gal com­pletes NASH ap­proval re­quest

Last year
News Briefing

Apel­lis shares tum­ble on re­ports of eye in­flam­ma­tion in pa­tients tak­ing Syfovre

Last year
R&D
Pharma

Eli Lil­ly's Pre­vail strikes po­ten­tial bil­lion-dol­lar AAV cap­sids deal with Sang­amo for neu­ro­log­i­cal dis­eases

Last year
Deals
Cell/Gene Tx

Up­dat­ed: Eli Lil­ly ex­pects FDA de­ci­sion on Alzheimer’s drug by end of year as it un­veils full PhI­II da­ta

Last year
R&D
Pharma

Turn­stone charts $75M IPO for TIL cell ther­a­pies in drum­roll of biotech IPOs this month

Last year
Financing
Startups

Ar­genx looks for quick la­bel ex­pan­sion for sub­cu­ta­neous Vyv­gart with PhII da­ta — shares soar

Last year
R&D
Pharma

Bridge­Bio's AT­TR-CM tri­al odyssey ends with a win, show­ing pos­i­tive mor­tal­i­ty and hos­pi­tal­iza­tion da­ta

Last year
R&D

Moon­Lake’s im­munol­o­gy drug gets help of in­vest­ment bankers for po­ten­tial sale — Reuters re­port

Last year
Deals
Pharma

West­lake at­tracts an­oth­er $450M to fu­el star­tups in LA's nascent biotech scene

Last year
Financing
Startups

Sin­gle in­jec­tion of Al­ny­lam's RNAi ther­a­py re­duces Alzheimer's-linked pro­teins by 65% for six months

Last year
R&D

Eli Lil­ly’s M&A Fri­day; No­var­tis' TIG­IT breakup; One big hire and one big ex­it; Re­verse merg­er, shut­down and white ...

Last year
Weekly

FTC says it wants more in­for­ma­tion about $43B Pfiz­er-Seagen deal

Last year
Deals
Pharma

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Last year
R&D

FDA cites clean­ing, main­te­nance is­sues at Catal­ent fa­cil­i­ty re­spon­si­ble for Re­gen­eron’s drug re­jec­tion

Last year
People
FDA+

House green­lights psy­che­del­ic re­search in NDAA, drug short­age and PBM re­forms to come

Last year
Pharma
FDA+

GAO of­fers 11 new poli­cies to im­prove re­gen­er­a­tive med­i­cine de­vel­op­ment in new re­port

Last year
Pharma
FDA+

No­vo Nordisk set to boost We­govy sup­plies with sec­ond man­u­fac­tur­er ready, and a third get­ting clos­er

Last year
Pharma
Manufacturing

UK's life sci­ences sec­tor sees $1.1B drop in for­eign in­vest­ments from 2021 to 2022

Last year
Financing
Pharma

Mark Cuban's Cost Plus Drug Com­pa­ny adds new SGLT2 in­hibitor Bren­zavvy for type 2 di­a­betes

Last year
Pharma
Marketing

Aca­dia gets more rights for Day­bue, fork­ing over $100M up­front af­ter an ‘im­pres­sive’ US launch

Last year
Deals

Lil­ly bets up to $1.9B on Ver­sanis' PhI­Ib weight loss drug alone and in com­bo with No­vo Nordisk's We­govy

Last year
Deals
Pharma

Io­vance clos­es $172.5M of­fer­ing; Vek­lury ap­proved for Covid-19 pa­tients with se­vere re­nal dis­ease

Last year
News Briefing

Cari­bou’s off-the-shelf CAR-T ther­a­py shows hints of dura­bil­i­ty in ear­ly cut of da­ta 

Last year
R&D
Cell/Gene Tx

Roivant dis­cussing sale of its Pfiz­er-part­nered UC drug to Roche for $7B, ac­cord­ing to re­port

Last year
Deals
R&D
First page Previous page 311312313314315316317 Next page Last page
A service from the Financial Times